

1H23 Results Presentation March 2023

Disclaimer

The following provisions apply to this presentation. Please consider its contents carefully.

Currency of information

The information contained in this presentation is current as at the date of this presentation or such earlier date as specified in this presentation.

Summary information

The information in this presentation is of a general nature only. It does not purport to be complete.

Not investment advice

The information contained in this presentation is not investment or financial product advice or any recommendation to acquire or sell securities in McPherson's Limited (ASX: MCP). This presentation has been prepared without taking into account your investment objectives, financial situation or particular needs.

Company information

MCP's historical information in this presentation is, or is based on, information that has been released to ASX. This presentation should be read in conjunction with MCP's other periodic and continuous disclosure information lodged with ASX, which are available at <u>www.asx.com.au</u>.

Third party information

Certain market and industry data used in connection with this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither MCP nor any of its related bodies corporate, directors, employees, agents or advisers have independently verified such market or industry data and no representation or warranty is made as to the accuracy, completeness or reliability of the information.

Historical information

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as, and is not, an indication of future performance.

Forward looking information

This presentation contains certain forward-looking statements that involve risks and uncertainties many of which are beyond MCP's control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. MCP can give no assurance that these expectations will prove to be correct. You are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from those anticipated in these forward-looking statements due to many important factors, risks and uncertainties including, without limitation, risks associated with future capital needs, general economic uncertainty and other risks detailed from time to time in MCP's announcements to ASX. MCP does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect new information events or circumstances after the date of this presentation, except as may be required under applicable laws.

Disclaimer

No representation or warranty, whether express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. You should carry out your own investigations and analysis of MCP and verify the accuracy, reliability and completeness of the information contained in this presentation.

Neither MCP nor any of its related bodies corporate, directors, employees, agents and advisers accept any responsibility for any loss arising from anyone acting or refraining from acting in reliance on the contents of this presentation.

Agenda

01 1H23 Overview

O2 Business Unit Performance

03 Financial Results

O4 Summary and Outlook



Our Speakers

GRANT PECK CEO & Managing Director



SUPRIYA SINGH Commercial Director - ANZ



PAUL WITHERIDGE CFO



JADE PEAK Commercial Director – International



1H23 Overview



\$112m TOTAL SALES REVENUE

▲ **3%** on 1H22: \$108.8m

\$8.9m UNDERLYING EBITDA ▼11% on 1H22: \$10.0m

10% GEARING NET DEBT: \$13.9m **▲7%** OWNED BRAND SALES

\$5.1m

▼ 24%

2.0 CPS

DIVIDEND

1H22: 3.0 cps

PBT

UNDERI YING

on 1H22: \$6.7m

1H23 Summary

- Sales growth of 3%, impacted by reduced private label (\$4.7m)
- Multix impacting on overall sales and profit growth: sales down \$1.7m or 6% for 1H23
- Strong growth in sales of HWB core owned brands, up 13% on 1H22, led by Manicare, Lady Jayne and increased ranging of Fusion
- Underlying EBITDA compression due to:
 - Lower Multix outcomes sales and margin
 - Increased A&P support for HWB
- Multix margin expected to improve in 2H23 and FY24
- Balance sheet remains strong
- Refinancing advanced and dividend approved.

Health, Wellness & Beauty

Demand dynamics

Increasing demand for sustainable solutions

*@,

Proactive beauty and beauty at home

Clean and efficacious solutions



β

Increasingly cost-conscious consumer

Consumers will prioritise health and beauty

Challenges



Global and local costs leaning toward inflationary setting



Seafreight, commodity and currency normalising in H2



International markets cautiously opening





Chemist Warehouse

On track to deliver first year of the business case"

Unique, two-way relationship created by the strategic alliance with Chemist Warehouse to deliver benefits to both parties:

- 1. McPherson's appointed exclusive distributor for select CWH brands, which are complementary to existing portfolio. Long-term arrangements will take time to gain momentum.
- 2. Provides mutual support for increased ranging of new MCP brands in CWH including Fusion.
- 3. Enhanced support for existing Essential Beauty brands including Swisspers, Manicare, Lady Jayne and Dr. LeWinn's.

The Strategic alliance supported McPherson's strong performance in pharmacy channel in 1H23.



Corporate Items

Material Items – Net \$4.1m charge

- Multix non-cash impairment of \$3.9m
- Other brands non-cash impairment of \$1.0m
- Favourable writeback of Dr. LeWinn's inventory provision of (\$1.0m)
- Other corporate costs \$0.2m mainly relating to integration of Health & ANZ CBUs

Group Refinance Update

Well advanced

ASIC Litigation Update

Company intends to defend









Channel / Category Performance

Core brands outperforming pharmacy channel growth, grocery channel more challenging

Total MCP Core Brands vs Pharmacy Channel Dollars Growth % Qtr vs YA



Total MCP vs Grocery Channel Dollars Growth % vs YA



Strong Demand for Our Brands



#1 Australian Cosmeceutical Pharmacy Brand One of the fastest growing VMS brands in Pharmacy #1 Beauty Tools & Accessories #1 Hair Tools & Accessories #1 Foil, Bake, Garbage & Freezer Bags

#1 Cotton Brand

Source: Data sourced from IRI MarketEdge based on data definitions provided by McPherson's Consumer Products. Australian Pharmacy & Grocery Weighted Market. Beauty Accessories , Hair Accessories Category MAT 01/01/23; Cotton, Facial Skincare, Haircare, BWF category MAT 01/01/23

Integration of Health

Successfully integrated the Health business unit into the larger Beauty business unit in ANZ during 1H23

- Improved service for customers with a single point of contact for field sales and consolidated orders, invoicing and delivery
- Achieved cost efficiencies by combining the selling, distribution and administration functions of these
 previously separate units.





ANZ – 1H23 Highlights



Segment Performance	1H23 (\$m)	1H22 (\$m)	Change (\$m)	Change (%)
Sales Revenue	107.1	105.1	2.0	2%
Underlying EBIT	11.6	13.6	(2.0)	(15%)


- Sales growth on all core brands excl. A'kin and Multix
- **Essential Beauty** products (Manicare, Lady Jayne and Swisspers) performing strongly with double digit growth, ahead of market
- Dr. LeWinn's supported by innovation in serums and increased ranging, reduced sales of A'kin
- **Fusion Health** sales up 30% v 1H'22 with further upside as ranging expands in Australia and New Zealand
- 16% growth in the **Pharmacy channel**, driven by distribution expansion

Multix

- Currency, commodity and sea-freight impacting contribution from Multix. Cost drivers are recovering but will take time to positively impact margins
- Pricing mitigations have been implemented but the category remains challenging
- The decision to reduce unprofitable private label business in Bags, Wraps and Foils category has also impacted sales

1H23 core brand sales vs 1H22					
Manicare	+11%				
Lady Jayne	+39%				
Dr. LeWinn's	+1%				
Swisspers	+17%				
Fusion Health	+30%				
A'Kin	-32%				
Multix	-5%				

Growth Tactics



ANZ - Core Brand Performance

Manicare and Lady Jayne continue to leverage the **Beauty at Home** trend, providing high quality **beauty tools** at affordable prices



Leader in sustainability and innovation with Swisspers eco cleansing pads and baby cotton



ANZ - Core Brand Performance

Dr. LeWinn's Serum Series launch drove strong growth and distribution expansion in addition to continued success of Marine Collagen




Fusion wins Self Care Excellence Award for second year in a row and invests behind a brand awareness marketing campaign



Awarded by Consumer HealthCare Products (CHP) Australia for calendar year 2022

International – 1H23 Highlights





Sales revenue and EBIT increase vs 1H22 alongside reset of channel strategy for Dr. LeWinn's in China



Capabilities are being reset



Platform is set for selective international expansion with prudent investment



Consumer activity in China continues to improve post the removal of restrictions in January



International Strategic Imperatives





M


3% Growth in 1H23 Sales Revenue

7% Growth in Owned Brand Sales

All figures \$m	1H23	1H22	% change	
Total Group Sales	112.0	108.8	3.0	
ANZ				
Essential Beauty	44.9	38.3	17.2	Manicare, Lady Jayne and Swisspers all recorded double-digit growth
Skin, Hair & Body	12.1	13.0	(7.4)	Slight growth in Dr. LeWinn's.
				32% decline in A'kin due in part to reduced ranging in grocery
Health	9.7	8.3	17.0	30% growth in Fusion Health driven by Strategic Alliance with Chemist Warehouse
Household Consumables & Others	32.3	33.1	(2.3)	5% decline in Multix due to weaker consumer environment
Total Owned Brands	99.0	92.7	6.8	
Agency brands	4.9	4.5	8.4	
Private Label	3.2	7.8	(59.0)	Reduction in participation in low margin bags, wraps and foils
Total Sales	107.1	105.1	1.9	
International				
Skin, Hair & Body	2.5	1.6	59.5	\$1.0m increase in Dr. LeWinn's sales in China
Other owned brands	0.3	0.4	(18.3)	
Total Owned Brands	3.6	2.7	32.4	
Agency brands	1.3	1.0	29.2	
Total Sales	4.9	3.7	31.6	

1H23 Underlying EBIT


EBIT impacted by cost increases, lower contribution from Multix and investment in advertising and promotion



MCPHERSON'S

5.8 1H2023

Low Gearing and Net Bank Debt



Net bank debt* (\$m – 31 December)

Highlights:

Net bank debt remains low at **\$13.9 million.**

Gearing remains low at **10%** at 31 December 2022

The Company had an operating cash outflow of \$6.0m for 1H23 largely due to seasonal increases in working capital.

Seasonal reduction in working capital over the six months to 30 June 2023 is forecast to result in strong 2H23 cash conversion.

Gearing^{*} % (31 December)

Interim Dividend

- Interim ordinary dividend of 2.0 cents per share (cps) fully franked (1H22 3.0 cps).
- Underlying payout ratio of 89%.
- Consistent with policy to pay a minimum of 60% of underlying profit after tax.
- Interim dividend payable 6 April 2023.








Sunnary E Outlook

We are Creating a Unique Platform to Enable Growth



)utlook

- ocus is unchanged, despite the challenging broader economic environment
- strong demand in Health, Wellness & Beauty category with esilient, well recognized and respected brands
- Creating a platform of capability in Health, Wellness and Beauty o support growth
- Restructured team, simplified and aligned by process, vision and values
- Innovation driving growth
- Right partnerships to facilitate and complement our strategy
- trong balance sheet and demonstrated cashflow capability upport business requirements in current environment
- Ve will address Multix with a focus against changing consumer lynamics as we cost optimize .
- approach in international markets will be selective.







Wellness | Beauty



ppendix 1: Further Commentary on nderlying Earnings

ue	HY23 (\$m) HY22 (\$m)		Var %	Further Commentary
revenue	112.0	108.8	3.0%	Refer detailed presentation
ncome	0.0	0.1	-51.2%	
evenue and other income	112.0	108.9	2.9%	
lying Expenses				
als and consumables	(58.8)	(57.3)	2.7%	Increase consistent with Revenue
yee costs	(19.8)	(19.6)	2.2%	
ising and promotions	(12.5)	(10.6)	17.2%	Investment to support growth in Fusion and essential beauty brands
e and freight	(3.6)	(3.4)	5.3%	Increase in volume (consistent with sales) and rates
arty warehousing	(1.2)	(1.0)	15.0%	Increase in inventory of Multix product
expenses	(0.2)	(0.3)	-39.2%	
of net loss of joint ventures accounted for using the equity method	0.0	(0.2)	-100.0%	
expenses	(7.0)	(6.5)	6.9%	Post covid lockdown, increase in travel expense of \$0.5m
ciation & amortisation	(3.0)	(2.8)	8.7%	
lying EBIT	5.9	7.2	-19.0%	
rrowing costs	(0.8)	(0.5)	40.5%	
lying profit before tax	5.1	6.7	-23.9%	

ppendix 2: Reconciliation of Underlying Statutory Profit/(Loss) Before Tax

Underlying profit before tax	1H23 (\$m) 5.1	1H22 (\$m) 6.7
<u>Significant items before tax included in statutory profit / (loss) before tax</u>		
Dr. LeWinn's inventory provision release	1.0	0.0
Impairment of Multix brand	(3.9)	0.0
Impairment of other brands	(1.0)	0.0
Restructuring expenses	(0.2)	(0.4)
Dr. LeWinn's inventory provision	0.0	(9.4)
Net favourable impact from the exit of joint ventures	0.0	0.4
Regulatory review expenses	0.0	(0.3)
Total significant items before tax	(4.1)	(9.7)
Statutory profit / (loss) before tax	1.0	(3.0)
Statutory income tax expense	(0.9)	0.9
Statutory profit / (loss) after tax	0.1	(2.1)

29